2型糖尿病的IGlarLixi:一个系统的审查和元分析
Yang Liu1, Congxin Li1, Xuejing Li1
1Department of Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang, China.
Endocrine
|May 13, 2024
概括
胰岛素glargine和lixisenatide组合 (iGlarLixi) 有效地改善了2型糖尿病的血糖控制. 虽然它通常是安全的,但可能会增加胃肠道副作用和症状性低血糖症.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2D) 的管理需要有效和安全的治疗选择.
- 固定比率组合有可能改善患者的坚持和结果.
研究的目的:
- 评估iGlarLixi的疗效和耐受性,iGlarLixi是一种新型的insulin glargine和lixisenatide可溶性组合.
- 评估iGlarLixi对T2D成年人血糖控制和安全的影响.
主要方法:
- 来自主要数据库 (PubMed,Embase,Cochrane,ClinicalTrials.gov) 的随机对照试验 (RCT) 的系统审查和元分析,截至2023年11月.
- 纳入了10项与6071名T2D患者的RCT,将iGlarLixi与安慰剂或其他抗糖尿病药物进行比较.
- 使用风险比率 (RRs) 和平均差异 (MDs) 的统计分析,使用95%的置信区间 (CI).
主要成果:
- iGlarLixi显著改善了HbA1c水平,并实现了血糖目标 (<7%,<6.5%,<7.0%,没有体重增加或严重低血糖症).
- 观察到对禁食血葡萄糖和自我测量血葡萄糖的有益影响.
- 严重的低血糖或严重的不良事件没有增加;然而,胃肠道事件和症状性低血糖更为频繁.
结论:
- iGlarLixi在T2D治疗中显示出有希望的疗效和普遍可接受的安全性.
- 建议进一步进行大规模的多中心RCT,以完善对iGlarLixi的长期疗效和临床决策安全性的理解.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Diabetes: Management and Pharmacotherapy
266
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
266
Carbohydrate Metabolism
11.0K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.0K
Insulin: Dosing Regimen and Adverse Effects
167
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
167
Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192


